{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:04:44Z","timestamp":1789236284490,"version":"build-2803163510"},"reference-count":161,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.radonc.2021.07.022","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T02:39:58Z","timestamp":1627526398000},"page":"55-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Advances in radiotherapy in bone metastases in the context of new target therapies and ablative alternatives: A critical review"],"prefix":"10.1016","volume":"163","author":[{"given":"Andr\u00e9 G.","family":"Gouveia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic C.W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8323-9567","authenticated-orcid":false,"given":"Peter J.","family":"Hoskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo N.","family":"Marta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Trippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Maranzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio F.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2021.07.022_b0005","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2021.07.022_b0010","first-page":"755","article-title":"The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain","volume":"19","author":"Pockett","year":"2010","journal-title":"Eur J Cancer Care"},{"key":"10.1016\/j.radonc.2021.07.022_b0015","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1056\/NEJM198507113130205","article-title":"The treatment of cancer pain","volume":"313","author":"Foley","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2021.07.022_b0020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.breast.2019.10.016","article-title":"Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: a prospective clinical trial","volume":"49","author":"David","year":"2020","journal-title":"Breast"},{"key":"10.1016\/j.radonc.2021.07.022_b0025","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2021.07.022_b0030","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2021.07.022_b0035","doi-asserted-by":"crossref","unstructured":"Sze WM, Shelley M, Held I, Mason M. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy - a systematic review of the randomised trials. Cochrane Database Syst Rev 2004;2002:CD004721. 10.1002\/14651858.CD004721.","DOI":"10.1002\/14651858.CD004721"},{"key":"10.1016\/j.radonc.2021.07.022_b0040","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1200\/JCO.2006.09.5281","article-title":"Palliative radiotherapy trials for bone metastases: a systematic review","volume":"25","author":"Chow","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0045","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.radonc.2018.01.003","article-title":"Update of the systematic review of palliative radiation therapy fractionation for bone metastases","volume":"126","author":"Rich","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0050","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/COC.0000000000000548","article-title":"Persistent use of extended fractionation palliative radiotherapy for medicare beneficiaries with metastatic breast cancer, 2011 to 2014","volume":"42","author":"Yu","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0055","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ijrobp.2018.02.037","article-title":"Michigan radiation oncology quality consortium. Contemporary statewide practice pattern assessment of the palliative treatment of bone metastasis","volume":"101","author":"Spratt","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.07.022_b0060","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijrobp.2020.09.030","article-title":"Behavioral determinants of canadian radiation oncologists' use of single fraction palliative radiation therapy for uncomplicated bone metastases","volume":"109","author":"Squires","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.07.022_b0065","doi-asserted-by":"crossref","unstructured":"Skamene S, Agarwal I, Makar M, Krishnan M, et al. Impact of a dedicated palliative radiation oncology service on the use of single fraction and hypofractionated radiation therapy among patients with bone metastases. Ann Palliat Med 2018;7:186-191. 10.21037\/apm.2017.11.02.","DOI":"10.21037\/apm.2017.11.02"},{"key":"10.1016\/j.radonc.2021.07.022_b0070","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ijrobp.2020.08.056","article-title":"Do coordinated knowledge translation campaigns persuade radiation oncologists to use single-fraction radiation therapy compared with multiple-fraction radiation therapy for bone metastases?","volume":"109","author":"Shahhat","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.07.022_b0075","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.prro.2016.08.001","article-title":"Palliative radiation therapy for bone metastases: update of an ASTRO Evidence-Based Guideline","volume":"7","author":"Lutz","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0080","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0959-8049(99)00331-7","article-title":"Risk of complications from bone metastases in breast cancer. Implications for management","volume":"36","author":"Plunkett","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2021.07.022_b0085","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jbo.2014.12.001","article-title":"A definition of \u201cuncomplicated bone metastases\u201d based on previous bone metastases radiation trials comparing single-fraction and multi-fraction radiation therapy","volume":"4","author":"Cheon","year":"2015","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0090","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ijrobp.2019.11.033","article-title":"Frequency of complicated symptomatic bone metastasis over a breadth of operational definitions","volume":"106","author":"Alcorn","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.07.022_b0095","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1159\/000082923","article-title":"The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer","volume":"67","author":"Delea","year":"2004","journal-title":"Oncology"},{"key":"10.1016\/j.radonc.2021.07.022_b0100","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.radonc.2015.10.015","article-title":"Incidence and treatment patterns of complicated bone metastases in a population-based radiotherapy program","volume":"118","author":"Tiwana","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0105","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2005.08.193","article-title":"Short-course versus split-course radiotherapy in metastatic spinal cord compression: results of a phase III, randomized, multicenter trial","volume":"23","author":"Maranzano","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0110","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.radonc.2008.05.018","article-title":"Randomized clinical trial with two palliative radiotherapy regimens in painful bone metastases: 30 Gy in 10 fractions compared with 8 Gy in single fraction","volume":"89","author":"Foro Arnalot","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0115","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0167-8140(99)00110-3","article-title":"The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study","volume":"52","author":"Steenland","year":"1999","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0120","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/jnci\/95.3.222","article-title":"Single- versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial","volume":"95","author":"van den Hout","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2021.07.022_b0125","doi-asserted-by":"crossref","first-page":"168","DOI":"10.21037\/apm.2018.12.04","article-title":"Palliation of bone metastases-exploring options beyond radiotherapy","volume":"8","author":"Saravana-Bawan","year":"2019","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.radonc.2021.07.022_b0130","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/00003086-198912000-00027","article-title":"Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures","volume":"249","author":"Mirels","year":"1989","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.radonc.2021.07.022_b0135","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.radonc.2017.05.010","article-title":"Efficacy of postoperative radiation treatment for bone metastases in the extremities","volume":"124","author":"Drost","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0140","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0360-3016(94)E0310-G","article-title":"Role of postoperative radiation therapy after stabilization of fractures caused by metastatic disease","volume":"31","author":"Townsend","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.07.022_b0145","doi-asserted-by":"crossref","first-page":"E1221","DOI":"10.1097\/BRS.0b013e3181e16ae2","article-title":"A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group","volume":"35","author":"Fisher","year":"2010","journal-title":"Spine"},{"key":"10.1016\/j.radonc.2021.07.022_b0150","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0140-6736(05)66954-1","article-title":"Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial","volume":"366","author":"Patchell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2021.07.022_b0155","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0360-3016(97)00128-4","article-title":"Short-course radiotherapy (8 Gy x 2) in metastatic spinal cord compression: an effective and feasible treatment","volume":"38","author":"Maranzano","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.07.022_b0160","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/0360-3016(95)00572-G","article-title":"Effectiveness of radiation therapy without surgery in metastatic spinal cord compression: final results from a prospective trial","volume":"32","author":"Maranzano","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.07.022_b0165","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/0360-3016(85)90285-8","article-title":"Radiation therapy in the treatment of metastatic renal cell carcinoma","volume":"11","author":"Onufrey","year":"1985","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.07.022_b0170","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1007\/s10434-000-0526-7","article-title":"Distant soft tissue metastases: a series of 30 new patients and 91 cases from the literature","volume":"7","author":"Damron","year":"2000","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0175","doi-asserted-by":"crossref","first-page":"181","DOI":"10.5301\/tj.5000658","article-title":"Hypofractionated radiotherapy for complicated bone metastases in patients with poor performance status: a phase II international trial","volume":"105","author":"Silva","year":"2019","journal-title":"Tumori"},{"key":"10.1016\/j.radonc.2021.07.022_b0180","doi-asserted-by":"crossref","unstructured":"8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Bone Pain Trial Working Party. Radiother Oncol 1999;52:111-21.","DOI":"10.1016\/S0167-8140(99)00097-3"},{"key":"10.1016\/j.radonc.2021.07.022_b0185","first-page":"261","article-title":"20 Gy in five fractions versus 8 Gy in one fraction in palliative radiotherapy of bone metastases: a multicenter randomized study","volume":"53","author":"Badzio","year":"2003","journal-title":"J Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0190","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/jnci\/dji139","article-title":"Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases","volume":"97","author":"Hartsell","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2021.07.022_b0195","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1470-2045(13)70556-4","article-title":"Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial","volume":"15","author":"Chow","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0200","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0205","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0210","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","article-title":"Tracking the evolution of non\u2013small-cell lung cancer","volume":"376","author":"Jamal-Hanjani","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2021.07.022_b0215","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0022-5223(97)70397-0","article-title":"International Registry of Lung Metastases. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases","volume":"113","author":"Pastorino","year":"1997","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.radonc.2021.07.022_b0220","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","article-title":"Oligometastases revisited","volume":"8","author":"Weichselbaum","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0225","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0230","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0235","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): five-year results of a randomized phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0240","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.eururo.2018.06.004","article-title":"Stereotactic ablative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial","volume":"74","author":"Siva","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2021.07.022_b0245","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1093\/annonc\/mds053","volume":"23","author":"Ruers","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0250","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cllc.2019.07.007","article-title":"Improved overall survival with comprehensive local consolidative therapy in synchronous oligometastatic non-small-cell lung cancer","volume":"21","author":"Mitchell","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.radonc.2021.07.022_b0255","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1186\/s12885-019-5977-6","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of 4\u201310 oligometastatic tumours (SABR-COMET-10): study protocol for a randomized phase III trial","volume":"19","author":"Palma","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2021.07.022_b0260","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/s12885-020-06876-4","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of 1\u20133 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial","volume":"20","author":"Olson","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2021.07.022_b0265","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ctrv.2016.11.013","article-title":"Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review","volume":"53","author":"Kroeze","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.radonc.2021.07.022_b0270","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/jnci\/djz101","article-title":"Systematic review of the role of stereotactic radiotherapy for bone metastases","volume":"111","author":"Spencer","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2021.07.022_b0275","unstructured":"National Comprehensive Cancer Network NCCN: Central Nervous System Cancers V3.2020 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cns.pdf Date: 2020 (september 11,2020. Accessed January 10, 2021)."},{"key":"10.1016\/j.radonc.2021.07.022_b0280","doi-asserted-by":"crossref","DOI":"10.3171\/foc.2005.18.3.9","article-title":"Combination kyphoplasty and spinal radiosurgery: a new treatment paradigm for pathological fractures","volume":"18","author":"Gerszten","year":"2005","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.radonc.2021.07.022_b0285","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/cncr.22977","article-title":"Cyberknife radiosurgery for breast cancer spine metastases: a matched-pair analysis","volume":"110","author":"Gagnon","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2021.07.022_b0290","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ijrobp.2009.07.1727","article-title":"Stereotactic radiosurgery for treatment of spinal metastases recurring in close proximity to previously irradiated spinal cord","volume":"78","author":"Choi","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.07.022_b0295","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1464-410X.2010.09895.x","article-title":"Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma","volume":"108","author":"Staehler","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.radonc.2021.07.022_b0300","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1002\/cncr.25918","article-title":"Prospective evaluation of spinal reirradiation by using stereotactic body radiation therapy: The University of Texas MD Anderson Cancer Center experience","volume":"117","author":"Garg","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2021.07.022_b0305","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.ijrobp.2010.08.012","article-title":"Stereotactic body radiotherapy reirradiation for recurrent epidural spinal metastases","volume":"81","author":"Mahadevan","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.07.022_b0310","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/1748-717X-6-173","article-title":"Spinal radiosurgery\u2013efficacy and safety after prior conventional radiotherapy","volume":"6","author":"Nikolajek","year":"2011","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0315","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3109\/0284186X.2012.666637","article-title":"Local tumour control after retreatment of spinal metastasis using stereotactic body radiotherapy; comparison with initial treatment group","volume":"51","author":"Chang","year":"2012","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0320","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3171\/2012.4.SPINE11902","article-title":"Single-session and multisession CyberKnife radiosurgery for spine metastases University of Pittsburgh and Georgetown University experience","volume":"17","author":"Heron","year":"2012","journal-title":"J Neurosurg Spine"},{"key":"10.1016\/j.radonc.2021.07.022_b0325","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/j.prro.2012.01.005","article-title":"The efficacy of external beam radiotherapy and stereotactic body radiotherapy for painful spinal metastases from renal cell carcinoma","volume":"2","author":"Hunter","year":"2012","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0330","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fonc.2012.00167","article-title":"Malignant melanoma and radiotherapy: past myths, excellent local control in 146 studied lesions at Georgetown University, and improving future management","volume":"2","author":"Jahanshahi","year":"2012","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0335","doi-asserted-by":"crossref","first-page":"15","DOI":"10.7785\/tcrt.2012.500230","article-title":"Minimal access spine surgery (MASS) for decompression and stabilization performed as an out-patient procedure for metastatic spinal tumours followed by spine stereotactic body radiotherapy (SBRT): first report of technique and preliminary outcomes","volume":"11","author":"Massicotte","year":"2012","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.radonc.2021.07.022_b0340","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1470-2045(11)70384-9","article-title":"Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1\u20132 trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0345","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/neuonc\/not101","article-title":"Surgical resection of epidural disease improves local control following postoperative spine stereotactic body radiotherapy","volume":"15","author":"Al-Omair","year":"2013","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0350","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3171\/2012.11.SPINE12111","article-title":"Local disease control for spinal metastases following \u201cseparation surgery\u201d and adjuvant hypofractionated or high-dose single-fraction stereotactic radiosurgery: outcome analysis in 186 patients","volume":"18","author":"Laufer","year":"2013","journal-title":"J Neurosurg Spine"},{"key":"10.1016\/j.radonc.2021.07.022_b0355","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.urolonc.2011.02.023","article-title":"Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer","volume":"31","author":"Muacevic","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0360","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.ijrobp.2013.12.042","article-title":"Outcomes and toxicity for hypofractionated and single-fraction image-guided stereotactic radiosurgery for sarcomas metastasizing to the spine","volume":"88","author":"Folkert","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.07.022_b0365","doi-asserted-by":"crossref","first-page":"e589","DOI":"10.1016\/j.prro.2015.05.004","article-title":"Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: is RCC truly radioresistant?","volume":"5","author":"Amini","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0370","article-title":"Spine stereotactic body radiotherapy outcomes in patients with concurrent brain metastases","volume":"8","author":"Colaco","year":"2016","journal-title":"Cureus"},{"key":"10.1016\/j.radonc.2021.07.022_b0375","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ijrobp.2015.03.029","article-title":"Salvage Stereotactic Body Radiotherapy (SBRT) following in-field failure of initial SBRT for spinal metastases","volume":"93","author":"Thibault","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.07.022_b0380","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3171\/2015.8.SPINE15844","article-title":"Single fraction versus multifraction spinal stereotactic radiosurgery for spinal metastases from renal cell carcinoma: secondary analysis of Phase I\/II trials","volume":"24","author":"Ghia","year":"2016","journal-title":"J Neurosurg Spine"},{"key":"10.1016\/j.radonc.2021.07.022_b0385","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3340\/jkns.2016.59.1.37","article-title":"Radiosurgery compared with external radiation therapy as a primary treatment in spine metastasis from hepatocellular carcinoma: a multicenter, matched-pair study","volume":"59","author":"Sohn","year":"2016","journal-title":"J Korean Neurosurg Soc"},{"key":"10.1016\/j.radonc.2021.07.022_b0390","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5301\/tj.5000441","article-title":"Stereotactic body radiotherapy of bone metastases in oligometastatic disease: prognostic factors of oncologic outcomes","volume":"102","author":"Ursino","year":"2016","journal-title":"Tumouri"},{"key":"10.1016\/j.radonc.2021.07.022_b0395","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.adro.2018.04.002","article-title":"Local failure and vertebral body fracture risk using multifraction stereotactic body radiation therapy for spine metastases","volume":"3","author":"Mehta","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0400","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.radonc.2018.04.030","article-title":"Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy","volume":"128","author":"Sprave","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0405","doi-asserted-by":"crossref","unstructured":"Ryu S, Deshmukh S, Timmerman RD, Movsas B, et al. Radiosurgery Compared To External Beam Radiotherapy for Localized Spine Metastasis: Phase III Results of NRG Oncology\/RTOG 0631. Presented at ASTRO 2019 Annual Meeting, Chicago, IL. Int J Radiat Oncol Biol Phys 2019;105: Supplement, S2\u2013S3.","DOI":"10.1016\/j.ijrobp.2019.06.382"},{"key":"10.1016\/j.radonc.2021.07.022_b0410","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.prro.2018.11.009","article-title":"Analysis of local control and pain control after spine stereotactic radiosurgery reveals inferior outcomes for hepatocellular carcinoma compared with other radioresistant histologies","volume":"9","author":"McGee","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0415","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2019.0192","article-title":"Single-fraction stereotactic vs conventional multifraction radiotherapy for pain relief in patients with predominantly nonspine bone metastases: a randomized phase 2 trial","volume":"5","author":"Nguyen","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0420","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.ijrobp.2020.09.019","article-title":"CCTG SC.24\/TROG 17.06: A randomized phase II\/III study comparing 24Gy in 2 Stereotactic Body Radiotherapy (SBRT) fractions versus 20Gy in 5 Conventional Palliative Radiotherapy (CRT) fractions for patients with painful spinal metastases","volume":"108","author":"Sahgal","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.07.022_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2021.01.004","article-title":"Phase 3 multi-center, prospective, randomized trial comparing single-dose 24 Gy radiation therapy to a 3-fraction SBRT regimen in the treatment of oligometastatic cancer","author":"Zelefsky","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.07.022_b0430","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.radonc.2020.01.030","article-title":"Single fraction radiosurgery, fractionated radiosurgery, and conventional radiotherapy for spinal oligometastasis (SAFFRON): a systematic review and meta-analysis","volume":"146","author":"Singh","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0435","doi-asserted-by":"crossref","first-page":"9397","DOI":"10.2147\/CMAR.S186630","article-title":"Single-Fraction Radiotherapy (SFRT) for bone metastases: patient selection and perspectives","volume":"11","author":"Loi","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.radonc.2021.07.022_b0440","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3171\/2016.8.SPINE16121","article-title":"Consensus guidelines for postoperative stereotactic body radiation therapy for spinal metastases: results of an international survey","volume":"26","author":"Redmond","year":"2017","journal-title":"J Neurosurg Spine"},{"key":"10.1016\/j.radonc.2021.07.022_b0445","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1016\/j.prro.2020.02.011","article-title":"Stereotactic body radiation therapy for nonspine bone metastases: international practice patterns to guide treatment planning","volume":"10","author":"Nguyen","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0450","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.radonc.2018.03.030","article-title":"Local control and fracture risk following stereotactic body radiation therapy for non-spine bone metastases","volume":"127","author":"Erler","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0455","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/j.prro.2013.05.006","article-title":"Outcomes and toxicities of stereotactic body radiation therapy for non-spine bone oligometastases","volume":"4","author":"Owen","year":"2014","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0460","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1001\/jamaoncol.2019.1449","article-title":"Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer: a phase 2 trial","volume":"5","author":"Bauml","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0465","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1164\/rccm.201610-2178LE","article-title":"Stereotactic ablative radiotherapy induces peripheral T-cell activation in patients with early-stage lung cancer","volume":"196","author":"de Goeje","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.radonc.2021.07.022_b0470","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijrobp.2018.09.001","article-title":"Prospective immunophenotyping of CD8+ T cells and associated clinical outcomes of patients with oligometastatic prostate cancer treated with metastasis-directed SBRT","volume":"103","author":"Evans","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.07.022_b0475","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2018.11.009","article-title":"Safety and efficacy of combined radiotherapy, immunotherapy and targeted agents in elderly patients: a literature review","volume":"133","author":"Belgioia","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.radonc.2021.07.022_b0480","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ijrobp.2009.02.037","article-title":"Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer","volume":"76","author":"Crane","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.07.022_b0485","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ijrobp.2010.02.030","article-title":"Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer","volume":"80","author":"Small","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.07.022_b0490","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.ijrobp.2014.01.017","article-title":"Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma","volume":"88","author":"Chen","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.07.022_b0495","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1200\/JCO.2009.24.7353","article-title":"Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab","volume":"28","author":"Spigel","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0500","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.ijrobp.2009.02.026","article-title":"External beam radiotherapy for prostate cancer patients on anticoagulation therapy: how significant is the bleeding toxicity?","volume":"76","author":"Choe","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.07.022_b0505","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.urology.2005.10.008","article-title":"A prospective evaluation of rectal bleeding after dose-escalated three-dimensional conformal radiation therapy using an intrarectal balloon for prostate gland localization and immobilization","volume":"67","author":"D'Amico","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.radonc.2021.07.022_b0510","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.beha.2009.01.001","article-title":"Thrombosis associated with angiogenesis inhibitors","volume":"22","author":"Elice","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.radonc.2021.07.022_b0515","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ijrobp.2015.02.016","article-title":"Gastrointestinal toxicities with combined antiangiogenic and stereotactic body radiation therapy","volume":"92","author":"Pollom","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.07.022_b0520","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.1016\/j.cllc.2017.10.008","article-title":"Lung toxicity in non-small-cell lung cancer patients exposed to ALK inhibitors: report of a peculiar case and systematic review of the literature","volume":"19","author":"Pellegrino","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.radonc.2021.07.022_b0525","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00428-017-2065-7","article-title":"Breast carcinoma subtypes show different patterns of metastatic behavior","volume":"470","author":"Moln\u00e1r","year":"2017","journal-title":"Virchows Arch"},{"key":"10.1016\/j.radonc.2021.07.022_b0530","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0535","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0540","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0545","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.breast.2019.05.001","article-title":"Concurrent radiotherapy with palbociclib or ribociclib for metastatic breast cancer patients: preliminary assessment of toxicity","volume":"46","author":"Ippolito","year":"2019","journal-title":"Breast"},{"key":"10.1016\/j.radonc.2021.07.022_b0550","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s12032-009-9395-5","article-title":"The impact of trastuzumab on radiation-induced pulmonary fibrosis: results of an experimental study","volume":"27","author":"Bese","year":"2010","journal-title":"Med Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0555","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ijrobp.2009.12.063","article-title":"Lapatinib in combination with radiation diminishes tumour regrowth in HER2+ and basal-like\/EGFR+ breast tumour xenografts","volume":"77","author":"Sambade","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.07.022_b0560","doi-asserted-by":"crossref","first-page":"13019","DOI":"10.1038\/ncomms13019","article-title":"Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize","volume":"7","author":"Adams","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.radonc.2021.07.022_b0565","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ijrobp.2015.01.020","article-title":"External beam radiation therapy and abiraterone in men with localized prostate cancer: safety and effect on tissue androgens","volume":"92","author":"Cho","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.07.022_b0570","article-title":"Phase II trial of enzalutamide and androgen deprivation therapy with salvage radiation in men with high-risk prostate-specific antigen recurrent prostate cancer: the STREAM trial","author":"Bitting","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cam4.315","article-title":"Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery","volume":"4","author":"Tazi","year":"2015","journal-title":"Cancer Med"},{"key":"10.1016\/j.radonc.2021.07.022_b0580","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"CA184-043 Investigators. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0585","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/COC.0000000000000199","article-title":"Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases","volume":"40","author":"Patel","year":"2017","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0590","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijrobp.2016.04.017","article-title":"Safety and efficacy of radiation therapy in advanced melanoma patients treated with ipilimumab","volume":"96","author":"Qin","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.07.022_b0595","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/annonc\/mdv622","article-title":"Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy","volume":"27","author":"Ahmed","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0600","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1002\/cncr.30138","article-title":"Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery","volume":"122","author":"Qian","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2021.07.022_b0605","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/CMR.0000000000000386","article-title":"Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination","volume":"27","author":"Aboudaram","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.radonc.2021.07.022_b0610","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/15384047.2016.1264543","article-title":"Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone","volume":"18","author":"Koller","year":"2017","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.radonc.2021.07.022_b0615","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13045-017-0511-2","article-title":"PD-1\/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy","volume":"10","author":"Long","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0620","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.3390\/ijms21124427","article-title":"Combination of ipilimumab and nivolumab in cancers: from clinical practice to ongoing clinical trials","volume":"21","author":"Kooshkaki","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.radonc.2021.07.022_b0625","first-page":"228","article-title":"Combination controversies: checkpoint inhibition alone or in combination for the treatment of melanoma?","volume":"32","author":"Warner","year":"2018","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.radonc.2021.07.022_b0630","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/apjon.apjon_3_19","article-title":"Management of immune-related adverse events associated with immune checkpoint inhibitor therapy: a minireview of current clinical guidelines","volume":"6","author":"Trinh","year":"2019","journal-title":"Asia Pac J Oncol Nurs"},{"key":"10.1016\/j.radonc.2021.07.022_b0635","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s00590-019-02446-y","article-title":"What's new in management of bone metastases?","volume":"29","author":"Errani","year":"2019","journal-title":"Eur J Orthop Surg Traumatol"},{"key":"10.1016\/j.radonc.2021.07.022_b0640","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/cncr.24837","article-title":"Percutaneous radiofrequency ablation of painful osseous metastases: a multicenter American College of Radiology Imaging Network trial","volume":"116","author":"Dupuy","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2021.07.022_b0645","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3174\/ajnr.A4595","article-title":"Radiographic local control of spinal metastases with percutaneous radiofrequency ablation and vertebral augmentation","volume":"37","author":"Wallace","year":"2016","journal-title":"Am J Neuroradiol"},{"key":"10.1016\/j.radonc.2021.07.022_b0650","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00270-016-1301-x","article-title":"Percutaneous thermal ablation of breast cancer metastases in oligometastatic patients","volume":"39","author":"Barral","year":"2016","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.radonc.2021.07.022_b0655","doi-asserted-by":"crossref","first-page":"dju082","DOI":"10.1093\/jnci\/dju082","article-title":"Magnetic resonance-guided focused ultrasound for patients with painful bone metastases: phase III trial results","volume":"106","author":"Hurwitz","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2021.07.022_b0660","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11547-012-0802-4","article-title":"Embolisation of bone metastases from renal cancer","volume":"118","author":"Rossi","year":"2013","journal-title":"Radiol Med"},{"key":"10.1016\/j.radonc.2021.07.022_b0665","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1055\/s-0030-1253510","article-title":"Embolization of musculoskeletal bone tumors","volume":"27","author":"Owen","year":"2010","journal-title":"Semin Intervent Radiol"},{"key":"10.1016\/j.radonc.2021.07.022_b0670","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11547-018-0938-8","article-title":"Percutaneous management of bone metastases: state of the art, interventional strategies and joint position statement of the Italian College of MSK Radiology (ICoMSKR) and the Italian College of Interventional Radiology (ICIR)","volume":"124","author":"Cazzato","year":"2019","journal-title":"Radiol Med"},{"key":"10.1016\/j.radonc.2021.07.022_b0675","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00508-019-1524-3","article-title":"Typical aspects in the rehabilitation of cancer patients suffering from metastatic bone disease or multiple myeloma","volume":"131","author":"Keilani","year":"2019","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.radonc.2021.07.022_b0680","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/09638288.2018.1514665","article-title":"Cancer rehabilitation: current trends and practices within an Austrian University Hospital Center","volume":"42","author":"Crevenna","year":"2020","journal-title":"Disabil Rehabil"},{"key":"10.1016\/j.radonc.2021.07.022_b0685","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 2015;386(10001):1353-1361. 10.1016\/S0140-6736(15)60908-4.","DOI":"10.1016\/S0140-6736(15)60908-4"},{"key":"10.1016\/j.radonc.2021.07.022_b0690","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0695","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0700","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2021.07.022_b0705","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1097\/JTO.0b013e31826aec2b","article-title":"Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study","volume":"7","author":"Scagliotti","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0710","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.jtho.2020.06.011","volume":"15","author":"Peters","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0715","doi-asserted-by":"crossref","first-page":"42979","DOI":"10.1038\/srep42979","article-title":"Bisphosphonates enhance antitumour effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.radonc.2021.07.022_b0720","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01243894-200610000-00017","article-title":"Increasing osteoblastic lesions as a manifestation of a major response to gefitinib","volume":"1","author":"Garfield","year":"2006","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0725","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2010.04.003","article-title":"Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases","volume":"71","author":"Sun","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2021.07.022_b0730","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s40425-019-0793-8","article-title":"Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer","volume":"7","author":"Landi","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.radonc.2021.07.022_b0735","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1480301","article-title":"An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer","volume":"7","author":"Liede","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.radonc.2021.07.022_b0740","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/CMR.0000000000000459","article-title":"Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center","volume":"28","author":"Afzal","year":"2018","journal-title":"Melanoma Res"},{"key":"10.1016\/j.radonc.2021.07.022_b0745","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00262-019-02353-5","article-title":"Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases","volume":"68","author":"Angela","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.radonc.2021.07.022_b0750","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.pmrj.2018.02.006","article-title":"Considerations for exercise prescription in patients with bone metastases: a comprehensive narrative review","volume":"10","author":"Sheill","year":"2018","journal-title":"PM R"},{"key":"10.1016\/j.radonc.2021.07.022_b0755","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1249\/MSS.0000000000001454","article-title":"Exercise preserves physical function in prostate cancer patients with bone metastases","volume":"50","author":"Galv\u00e3o","year":"2018","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.radonc.2021.07.022_b0760","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1249\/MSS.0b013e3181e0c112","article-title":"American College of Sports Medicine. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors","volume":"42","author":"Schmitz","year":"2010","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.radonc.2021.07.022_b0765","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1634\/theoncologist.2012-0293","article-title":"The NOMS framework: approach to the treatment of spinal metastatic tumors","volume":"18","author":"Laufer","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.radonc.2021.07.022_b0770","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1017\/S031716710001177X","article-title":"Contemporary treatment strategy for spinal metastasis: the \u201cLMNOP\u201d system","volume":"38","author":"Paton","year":"2011","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.radonc.2021.07.022_b0775","doi-asserted-by":"crossref","first-page":"e720","DOI":"10.1016\/S1470-2045(17)30612-5","article-title":"An integrated multidisciplinary algorithm for the management of spinal metastases: an International Spine Oncology Consortium report","volume":"18","author":"Spratt","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2021.07.022_b0780","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.4143\/crt.2017.223","article-title":"The NEAT predictive model for survival in patients with advanced cancer","volume":"50","author":"Zucker","year":"2018","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.radonc.2021.07.022_b0785","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ijrobp.2014.07.051","article-title":"An easy tool to predict survival in patients receiving radiation therapy for painful bone metastases","volume":"90","author":"Westhoff","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.07.022_b0790","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ijrobp.2020.05.023","article-title":"Developing an improved statistical approach for survival estimation in bone metastases management: the Bone Metastases Ensemble Trees for Survival (BMETS) model","volume":"108","author":"Alcorn","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2021.07.022_b0795","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1302\/0301-620X.95B2.29323","article-title":"The Oswestry Risk Index: an aid in the treatment of metastatic disease of the spine","volume":"95","author":"Balain","year":"2013","journal-title":"Bone Joint J"},{"key":"10.1016\/j.radonc.2021.07.022_b0800","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1503\/cjs.012013","article-title":"A comparison of the modified Tokuhashi and Tomita scores in determining prognosis for patients afflicted with spinal metastasis","volume":"57","author":"Aoude","year":"2014","journal-title":"Can J Surg"},{"key":"10.1016\/j.radonc.2021.07.022_b0805","doi-asserted-by":"crossref","first-page":"262","DOI":"10.5312\/wjo.v5.i3.262","article-title":"Scoring system for prediction of metastatic spine tumor prognosis","volume":"5","author":"Tokuhashi","year":"2014","journal-title":"World J Orthop"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814021066652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814021066652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:18:13Z","timestamp":1759123093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814021066652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":161,"alternative-id":["S0167814021066652"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2021.07.022","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in radiotherapy in bone metastases in the context of new target therapies and ablative alternatives: A critical review","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2021.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}